orforglipron

From Aaushi
Jump to navigation Jump to search
[1]

Indications

Dosage

  • 3 mg, 12 mg, or 36 mg once daily

Adverse effects

Notes

  • lowers HgbA1c 1.2-1.5%
  • reduces weight 4.5% (3-mg), 5.8% (12-mg) 7.6% (36-mg)

More general terms

References

  1. ↑ Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Jun 21. PMID: https://pubmed.ncbi.nlm.nih.gov/40544435 https://www.nejm.org/doi/10.1056/NEJMoa2505669

Database

Retrieved from "https://aaushi.info/w/index.php?title=A59250&oldid=1268130"